13F Holdings
中文EN

TNBI Tanke Biosciences Corp

Grain Mill Products · OTC · SEC CIK 1452011 · Fiscal year ends 12/31

Financial factors as of 2013-09-30 (2013Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY-19.5%
TTM net income YoY-164.1%
TTM EPS YoY-165.0%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin32.3%
Operating margin-0.2%
Net margin-7.1%
FCF margin-27.3%
EBITDA margin2.1%

Returns

ROE-10.2%
ROA-5.7%
ROIC (approx.)-0.4%
Asset turnover0.80x

Leverage & solvency

Liabilities / assets45.5%
Debt / equity0.12x
Current ratio1.61x
Interest coverage-0.10x

Cash quality & payout

Operating cash flow / net income2.30x
Accruals ratio7.4%
Payout ratio—
Capex / revenue10.8%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20122012-12-31FY20112011-12-31FY20102010-12-31FY2009*2009-12-31
Income statement
Revenue$28.56M$23.83M$20.10M—
Cost of revenue$18.62M$15.06M$12.70M—
Gross profit$9.94M$8.77M$7.40M—
R&D expense$290,691$246,038——
SG&A expense$2.57M$4.49M$834,761—
Operating income$4.53M$1.74M$4.37M—
Interest expense$1.45M$1.36M$100,265—
Pretax income$602,591-$2.45M$4.28M—
Income tax$831,597$681,321$582,493—
Net income-$210,247-$3.14M$2.74M$2.58M
EBITDA$5.17M$2.14M$4.51M—
EPS (basic)-0.02-0.240.34—
EPS (diluted)-0.02-0.240.34—
Weighted avg. shares (diluted)13.32M13.08M10.76M—
Balance sheet
Cash & equivalents$6.17M$7.70M$2.22M$1.82M
Receivables$1.99M$1.92M$1.77M—
Inventory$1.41M$1.19M$1.35M—
Current assets$22.37M$18.91M$7.67M—
PP&E, net$4.81M$4.77M$1.55M—
Intangibles$1.24M$838,089$242,417—
Total assets$28.85M$24.89M$13.27M—
Current liabilities$12.10M$3.55M$2.41M—
Short-term debt$1.27M$785,456$905,975—
Long-term debt$792,567$628,365$452,987—
Total debt$2.06M$1.41M$1.36M—
Total liabilities$12.93M$9.03M$2.93M—
Shareholders' equity$15.75M$15.85M$8.16M$6.44M
Net debt-$4.11M-$6.29M-$863,063—
Shares outstanding13.32M13.32M10.76M—
Cash flow statement
Operating cash flow-$1.18M$3.65M$4.38M—
Capital expenditure$856,361$701,022$76,071—
Free cash flow-$2.04M$2.95M$4.31M—
Investing cash flow-$1.53M-$3.67M-$2.82M—
Financing cash flow$1.12M$5.82M-$1.22M—
Depreciation & amortization$636,286$400,013$136,140—
Stock-based compensation—$2.49M$0—

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.